



Oregon

Kate Brown, Governor

Oregon Department of Human Services

Office of Aging and People with Disabilities

Safety, Oversight and Quality

PO Box 14530, Salem, OR 97309

550 Capitol Street NE, Salem, OR 97301

Phone: (503) 373-2227

Fax (503) 378-8966

NF-22-028 – Provider Alert



Date: April 18, 2022

To: All Nursing Facilities
All Assisted Living Facilities
All Residential Care Facilities

From: Jack Honey, Administrator
Safety, Oversight and Quality Unit,
Office of Aging and People with Disabilities

Subject: OHA update on COVID-19 therapeutics

Oregon Health Authority update on COVID-19 therapeutics

Oregon Health Authority (OHA) is currently allocating several medications to treat or prevent COVID-19. OHA is committed to doing this in a way that ensures access for cultural communities that have been hit hardest by severe COVID-19 illness as well as older adults, who could be at higher risk for severe illness.

Long-term care facilities may sign up to order these medications (described below) through OHA. Facilities may place orders for these products as frequently as once a week, based on utilization. **Please note:** Supplies are still limited, and OHA might not be able to fill all requests, depending on demand.

Treatment of COVID-19

The following medications are available through allocation from OHA for treatment of COVID-19 in those at high risk of severe illness. The three options available are: *Paxlovid* ([EUA](#)), *Molnupiravir* ([EUA](#)), and *Bebtelovimab* ([EUA](#)). A summary of these medicines is provided, below.

Medication	How It's Given	Evidence for Effectiveness	Clinical Considerations
<i>Paxlovid</i>	Orally twice daily for 5 days	Reduces risk of hospitalization or death by 88%	<ul style="list-style-type: none"> • Significant drug-drug interactions • Avoid in severe kidney or liver disease • Adjust dose for renal impairment • Start within 5 days of symptom onset
<i>Molnupiravir</i>	Orally twice daily for 5 days	Reduces risk of hospitalization or death by 30%	<ul style="list-style-type: none"> • Option if other therapies aren't available • Avoid in children or during pregnancy • Start within 5 days of symptom onset
<i>Bebtelovimab</i>	By vein, given over 30 seconds	Decreases amount of virus in body; shortens symptom duration	<ul style="list-style-type: none"> • Option if other therapies aren't available • Start within 7 days of symptom onset

Pre-exposure Prevention of COVID-19

Therapeutic agents for prevention are available for people with moderate or severe immunocompromise who might not have an adequate response to COVID-19 vaccine or who have medical contraindications to COVID-19 vaccination. Though it can't replace vaccination, *Evusheld* ([EUA](#)) can help prevent COVID-19 if vaccine can't provide sufficient protection.

Therapeutic Agent	How It's Given	Evidence of Effectiveness	Clinical Considerations
<i>Evusheld</i>	Two intramuscular injections in separate sites, preferably the gluteal muscles	Reduces risk of symptomatic COVID-19 infection by 77%	<ul style="list-style-type: none"> • Caution with use in those with known cardio-vascular disease • Do not administer within 2 weeks of COVID-19 vaccine • May repeat dosing every 6 months

Ways long-term care facilities can receive COVID-19 medications

There are currently two ways to receive these medicines, which are listed below. Facilities may also visit OHA's COVID-19 [monoclonal antibody](#) and [antiviral](#) webpages. These pages include OHA's Provider Operations Manual, information on how to register, place orders, and additional useful information regarding COVID-19 therapeutics.

Option 1: Coordinate with your Long-Term Care Pharmacy (Preferred)

- The pharmacy will order the medications directly from OHA.
- OHA will then supply the medications to the designated pharmacy.
- The designated pharmacy will distribute the medications to the LTCF sites.
- OHA can help register your pharmacy if they are not currently listed as an ordering site.

Option 2: Submit survey order requests directly to OHA (Providers with Dispensing Privileges Required)

- Notify OHA that you are interested in ordering COVID-19 therapies via email at OHA.therapeutics@dhsoha.state.or.us.
- After OHA receives your request to begin ordering, you will receive an email from OHA to complete the [COVID-19 Therapeutics Provider Registration Survey](#).
- Once registered, OHA will email the links to the ordering survey every Monday.
- **Surveys are due on Wednesdays by 11:59 p.m.** to be considered for allocation that week.

For questions on this update, contact OHA.therapeutics@dhsoha.state.or.us.

If you have licensing questions, please contact your licensing team:

- Adult Foster Home: APD.AFHTeam@dhsoha.state.or.us
- Residential Care and Assisted Living Facilities: CBC.team@dhsoha.state.or.us
- Nursing Facilities: NF.licensing@dhsoha.state.or.us

General questions may be sent to: SOQ.LTCInfo@dhsoha.state.or.us

Oregon Department of Human Services website: www.oregon.gov/DHS/